Patent SG-11201901206S-A (SG)
Title: Trimer stabilizing hiv envelope protein mutations
Inventor: RUTTEN LUCY
IPC: C07K14/005
Filed: 2017-09-14
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0111010101111101111101 0 01111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/050747 Al 22 March 2018 (22.03.2018) WIP0 I PCT (51) International Patent Classification: Declarations under Rule 4.17: A61K 39/12 (2006.01) C07K 14/005 (2006.01) — as to applicant's entitlement to apply for and be granted a (21) International Application Number: patent (Rule 4.17(ii)) PCT/EP2017/073141 — of inventorship (Rule 4.17(iv)) (22) International Filing Date: Published: 14 September 2017 (14.09.2017) — with international search report (Art. 21(3)) — (25) Filing Language: English before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (26) Publication Language: English amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) (30) Priority Data: 16188866.4 15 September 2016 (15.09.2016) EP (71) Applicant: JANSSEN VACCINES & PREVENTION B.V. [NL/NL]; Archimedesweg 4, 2333 CN Leiden (NL). (72) Inventors: RUTTEN, Lucy; Archimedesweg 4-6, 2333 CN Leiden (NL). TRUAN, Daphne; Archimedesweg 4-6, 2333 CN Leiden (NL). STROKAPPE, Nika, Mindy; Archimedesweg 4-6, 2333 CN Leiden (NL). _ LANGEDIJK, Johannes, Petrus, Maria; Archimedesweg 4-6, 2333 CN Leiden (NL). — = Agent: VERHAGE, Richard, A et al.; Archimedesweg (74) 4-6, 2333 CN Leiden (NL). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (81) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. _ Designated States (unless otherwise indicated, for every — (84) _ _ kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = 1-1 IN 71- (54) Title: TRIMER STABILIZING HIV ENVELOPE PROTEIN MUTATIONS IN 0 (57) : Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the en- i ln 0 velope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope ----- protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved GC trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also 1-1 © provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV f'1 envelope proteins, nucleic acid, and vectors. 0